Long-term Outcome of Osteonecrosis of the Jaw after Fosamax Exposure

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Communication to Focused Risk Awareness

General health and science communication has long emphasized the importance of informed patient awareness regarding prescription medications. This legacy includes broad educational efforts about drug benefits, side effects, and the need for monitoring during treatment. Within this framework, bisphosphonate therapies such as Fosamax have been widely prescribed for bone density management, with patient education focusing on typical gastrointestinal tolerability and adherence. Over time, clinical observations have expanded the scope of safety discussions to include less common but serious adverse events, notably osteonecrosis of the jaw (ONJ). This condition, characterized by exposed necrotic bone in the maxillofacial region, has emerged as a significant concern for patients with prolonged Fosamax exposure. The transition from general health information to a more focused risk assessment involves understanding the long-term prognosis of ONJ, including healing potential, need for surgical intervention, and impact on quality of life.

Bridging to Occupational and Clinical Contexts

This shift in emphasis naturally leads to examining how occupational settings—particularly those involving dental procedures, oral surgery, or healthcare roles with patient counseling responsibilities—may require heightened awareness of ONJ risks associated with Fosamax use. The following discussion addresses these occupational exposure considerations and provides a detailed analysis of the long-term prognosis of ONJ after Fosamax exposure, drawing on evidence from FDA labeling and epidemiological research.

Clinical Presentation and Risk Factors of ONJ

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use, however, has been associated with a rare but serious adverse effect: osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ involves delayed healing of the jawbone, often following invasive dental procedures such as tooth extraction, dental implants, or boney surgery (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Known risk factors include diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Mechanistically, bisphosphonate-related ONJ involves altered bone remodeling and impaired vascularity in the jawbone, though the precise pathways are still under investigation. A multiscale characterization of jawbone tissue has been proposed to better understand these responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Prognosis and Long-term Outcome

Regarding prognosis, the long-term outcome of ONJ after Fosamax exposure varies. According to FDA labeling, the time to onset of symptoms after starting the drug can range from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, but a subset may have recurrence of symptoms if rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk of ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These findings suggest that early recognition and cessation of Fosamax are critical for improving prognosis. Population-level data from a cohort study among cancer-free female patients aged 40-89 in the United Kingdom Clinical Practice Research Datalink provide additional insight into long-term risk and prognosis. The study found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). However, absolute risks remained low, at approximately 0.05% after 5 years, and diminished after discontinuation of treatment (https://pubmed.ncbi.nlm.nih.gov/39400702/). This indicates that while the relative risk increases with longer exposure, the absolute risk of developing ONJ is small, and prognosis improves after stopping the drug.

Adequacy of Warnings and Clinical Implications

The adequacy of warnings regarding Fosamax and ONJ is addressed in FDA labeling. The label explicitly states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). It also advises discontinuation if severe symptoms develop and notes that most patients have relief after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). These warnings are consistent with the evidence from epidemiological studies, which confirm that risk increases with duration but remains low in absolute terms and diminishes after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). For affected patients, prognosis-related considerations include the need for dental evaluation before starting therapy, especially in those with risk factors, and monitoring for symptoms such as jaw pain, swelling, or non-healing sores. The label also notes that in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that not all jaw symptoms are attributable to the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, the long-term prognosis of ONJ after Fosamax exposure is generally favorable for most patients, with symptom relief following drug discontinuation. However, risk increases with longer exposure, and a subset of patients may experience recurrence if rechallenged. The evidence supports the adequacy of current warnings, which emphasize risk factors, the importance of dental care, and the potential benefit of treatment cessation. Clinicians should weigh the benefits of Fosamax for osteoporosis against the low absolute risk of ONJ, particularly in patients with additional risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the long-term prognosis for osteonecrosis of the jaw after Fosamax exposure?

The long-term prognosis is generally favorable for most patients. According to FDA labeling, most patients experience relief of symptoms after discontinuing Fosamax, though a subset may have recurrence if rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Population data show that absolute risk is low (about 0.05% after 5 years) and diminishes after stopping treatment (https://pubmed.ncbi.nlm.nih.gov/39400702/).

How does the duration of Fosamax use affect the risk of ONJ?

The risk of ONJ increases with longer duration of bisphosphonate use. A cohort study found that risk was threefold higher after 2-3 years and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). However, absolute risks remain low, and the risk diminishes after discontinuation.

What are the known risk factors for developing ONJ while on Fosamax?

Known risk factors include cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures, and invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.